Answers are grounded in this paper and cite their sources.
Background Coccidioidomycosis is a frequent cause of community acquired pneumonia (CAP) in endemic areas of the United States. Methods This observational study included persons ≥ 14 years of age with CAP at Arizona or California study sites. The primary outcome was prevalence of PPC among patients with CAP. Secondary outcomes included predictors of PPC among those with CAP and clinical improvement in PPC. Associations between the SAnds-PPC clinical score over time and receipt of antifungal therapy among those with PPC were analyzed in a linear mixed model. Results Among 496 participants with CAP, the prevalence of PPC was 23.4% (95% CI: 19.9, 27.3). The odds of having PPC decreased for each year increase in age (odds ratio [OR]: 0.98; 95% CI: 0.97, 1.00); was lower for females than males (OR: 0.55; 95% CI: 0.33, 0.93); and higher for Hispanic ethnicity versus non-Hispanic ethnicity (OR: 1.98; 95% CI: 1.08, 3.64) Among 215 participants with PPC, a 50% reduction in the SAnds-PPC score (clinical response) was achieved by 67% of participants by Day 85, respectively. A linear mixed model controlling for visit, age, site, ethnicity, race and asthma history did not detect a difference in the average SAnds-PPC scores over time between participants who did and did not receive antifungal therapy (Parameter Estimate 0.79; 95% CI: -0.09, 1.67). Conclusions This study ascertained a high prevalence of coccidioidomycosis among patients with CAP in endemic areas. This study was not designed to definitively determine the impact of antifungal therapy for PPC.
No takes yet. Share an insight, caveat, or question.
Truong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: